VXA-301

VXA-301 is a bispecific antibody-drug conjugate (BiTAC-ADC) currently in the discovery stage, developed by VERAXA Biotech for the treatment of solid tumors. The drug is engineered using VERAXA's proprietary BiTAC platform, which enables the site-specific conjugation of cytotoxic payloads to bispecific antibodies. By targeting two distinct tumor-associated antigens or epitopes, VXA-301 is designed to improve tumor specificity and potency while minimizing off-target effects compared to traditional monospecific ADCs. The platform utilizes advanced click-chemistry for precise payload attachment, aiming to enhance the therapeutic index of the conjugate.